| I-22 Seiichi Hayato Population pharmacokinetics and exposure-response analyses of amyloid PET SUVr and plasma biomarkers Aβ42/40 ratio and p-tau181 for lecanemab in subjects with early Alzheimer’s disease Wednesday 09:45-11:15 |
| I-22 Seiichi Hayato Population pharmacokinetics and exposure-response analyses of amyloid PET SUVr and plasma biomarkers Aβ42/40 ratio and p-tau181 for lecanemab in subjects with early Alzheimer’s disease Wednesday 09:45-11:15 |